avibactam (Avycaz) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, covalent, slowly reversible β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. The combination of ceftazidime with avibactam exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae. AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam indicated for the treatment of patients with the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole and Complicated Urinary Tract Infections, including Pyelonephritis.   NCATS

  • SMILES: NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
  • Mol. Mass: 265.25
  • ALogP: -1.53
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( avibactam (Avycaz), ceftazidime (fortaz) - other names: avibactam and ceftazidime, zavicefta, ceftazidime-avibactam )
ave1330a | avibactam | avibactam - ceftazidime | avibactam, ceftazidime drug combination | avibactam sodium | avycaz | ceftazidime / avibactam | ceftazidime-avibactam | nxl104 | nxl 104 | nxl-104


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue